STOCK TITAN

THE TRENDLINES GRP SP/ADR - TRNLY STOCK NEWS

Welcome to our dedicated page for THE TRENDLINES GRP SP/ADR news (Ticker: TRNLY), a resource for investors and traders seeking the latest updates and insights on THE TRENDLINES GRP SP/ADR stock.

The Trendlines Group SP/ADR (TRNLY) is a leading investment group based in Israel and Singapore, specializing in identifying, investing in, and developing technologies with high growth potential in the medical and agrifood sectors. Through strategic partnerships and collaborations, The Trendlines Group nurtures innovative startups, driving advancements in healthcare, agriculture, and sustainability. Recently, The Trendlines Group has been involved in funding breakthrough companies such as Vessi Medical, ZygoFix, Limaca, and Ceretrieve, supporting cutting-edge solutions for bladder cancer treatment, spinal fusion technology, endoscopic ultrasound biopsies, and stroke care.

Rhea-AI Summary

Limaca Medical's Precision-GI™ endoscopic biopsy device has been granted transitional pass-through (TPT) payment by CMS, effective January 1, 2025, for up to three years. The device, which received FDA Breakthrough Device Designation in 2022 and FDA clearance in August 2023, is designed to improve biopsy results for gastrointestinal cancers. The motorized, automated rotating cutting mechanism enables superior tissue acquisition with less blood content in a single pass, enhancing diagnostic efficiency. The TPT program will support broader patient access by providing additional payments to hospitals to cover adoption costs. The device began its U.S. market entry in September 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

ElastiMed has appointed Dr. Amir Belson to its Board of Directors. Dr. Belson brings extensive experience in the medical device industry, having founded several successful companies including Neoguide Systems (acquired by Intuitive Surgical), Vascular Pathways (acquired by C.R. Bard), and Zipline Medical (acquired by Stryker). The appointment comes as ElastiMed prepares to bring its innovative compression therapy device to market. The company focuses on developing wearable medical devices for lymphatic and venous disease patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Vensica Medical has secured an $11 million funding round led by Israel Biotech Fund (IBF), with participation from strategic partners Merz and Laborie. The funding will support Phase 2 clinical trials in the US and Europe for their innovative overactive bladder (OAB) treatment. The company's proprietary technology delivers botulinum toxin A (Xeomin®) through a needle-free device directly to the bladder wall, offering a potentially less invasive alternative to traditional injections. Through its partnership with Merz, Vensica has obtained exclusive rights to Xeomin® for needle-less applications in various urologic indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Arcuro Medical has announced a significant milestone, surpassing 4,000 surgical cases worldwide and 1,000 cases in the U.S. with its SuperBall™ Meniscal Repair System. The current version, launched in 2022 with line extensions in 2023, addresses a full range of meniscus tear patterns. CEO Jamal Rushdy expressed excitement about the achievement and future growth prospects.

Dr. Philip Davidson, Arcuro's Medical Director, highlighted the system's unique tensioning mechanism, which provides superior strength and reduced complications compared to other devices. Arcuro has recently made key hires in the U.S., including Jamal Rushdy as CEO and Nick Tonno as Sales Director, to focus on commercial growth. The company plans to provide updates at upcoming industry events in Las Vegas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Dasyo, a pioneer in noninvasive medical aesthetics technologies, has appointed Domenic (Dom) Serafino as Executive Board Chair. Serafino brings extensive industry experience, having co-founded and led Venus Concept Inc. to over $100 million in annual revenues. He was also instrumental in Syneron Medical Corp's successful IPO. Dasyo, funded by the Israel Innovation Authority and The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), is developing a groundbreaking non-surgical breast lift product using proprietary technology for noninvasive directional skin tightening. This appointment is expected to significantly enhance Dasyo's strategic direction and growth potential in the aesthetics medical device sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Ceretrieve announced successful results of its multicenter, single-arm study for its aspiration catheter, aimed at treating acute ischemic stroke (AIS) caused by large vessel occlusion (LVO).

The study involved 20 patients and achieved 100% Complete/Near-Complete Perfusion with the Gen 2 device, far exceeding the 30%-40% rate of current gold-standard devices.

Ceretrieve's device allows single-pass clot removal and full blood flow restoration, ensuring high safety by minimizing the risk of clot fragments moving further into the brain.

The technology demonstrated superior performance compared to existing devices, highlighting its potential to significantly improve post-stroke patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Limaca Medical announced the successful completion of 24 cases using its Precision-GI™ endoscopic ultrasound guided motorized fine needle biopsy (EUS-mFNB) device on May 15, 2024. The device, used in both pancreatic and liver biopsies, showed significant tissue acquisition capabilities. Six cases involved the pancreas and eighteen the liver. Two-thirds of the cases were completed with a single needle pass, achieving top-grade biopsy samples in 21 out of 24 cases. The Precision-GI™ device, designed to obtain biopsies for definitive diagnoses of gastrointestinal cancers, has received FDA Clearance and Breakthrough Device Designation. Dr. Carlos Robles-Medranda, who led the study, praised the device for its efficiency and quality of biopsy tissue obtained.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

ZygoFix, a Trendlines portfolio company, has received FDA clearance for its zLOCK Lumbar Facet Fixation System, revolutionizing spinal fusion surgery. The system, backed by strong clinical evidence, offers a minimally invasive procedure with long-term pain reduction benefits. With CE certification and successful clinical utilization, ZygoFix is poised to make a significant impact in the US market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary

Arcuro Medical appointed Jamal Rushdy, a seasoned MedTech industry veteran, as its new CEO. Rushdy brings over 28 years of experience in orthopedics and sports medicine. The company aims to enhance patient care with their SuperBall™ technology for meniscus repair. Lee Ranon, the co-founder, transitions to the COO role. The board expresses confidence in Rushdy's leadership for the company's growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
Vessi Medical Ltd. closes a $16.5 million Series A financing round for its cryotherapy technology to treat Non Muscle Invasive Bladder Cancer, with key investors including an undisclosed global strategic investor, ALIVE- Israel HealthTech Fund, and Agriline. The technology aims to provide a minimally invasive solution for NMIBC, potentially improving quality of life. The financing will support R&D, clinical studies, and regulatory clearance to bring the treatment to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of THE TRENDLINES GRP SP/ADR (TRNLY)?

The current stock price of THE TRENDLINES GRP SP/ADR (TRNLY) is $2.086 as of October 4, 2024.

What is the market cap of THE TRENDLINES GRP SP/ADR (TRNLY)?

The market cap of THE TRENDLINES GRP SP/ADR (TRNLY) is approximately 41.8M.

What is The Trendlines Group SP/ADR (TRNLY)?

The Trendlines Group SP/ADR (TRNLY) is an Israel-based investment group specializing in identifying, investing in, and developing technologies with high growth potential in the medical and agrifood sectors.

What sectors does The Trendlines Group focus on?

The Trendlines Group focuses on healthcare, agriculture, and sustainability sectors, driving advancements through strategic partnerships and collaborations.

What recent investments has The Trendlines Group made?

The Trendlines Group has recently been involved in funding breakthrough companies like Vessi Medical, ZygoFix, Limaca, and Ceretrieve, supporting innovative solutions for bladder cancer treatment, spinal fusion technology, endoscopic ultrasound biopsies, and stroke care.

What is the core business of The Trendlines Group?

The Trendlines Group's core business is to nurture and develop innovative startups in the medical and agrifood sectors, driving advancements in healthcare, agriculture, and sustainability through strategic investments.

Where is The Trendlines Group based?

The Trendlines Group is headquartered in Israel and has a significant presence in Singapore, focusing on identifying and supporting technologies with high growth potential.

THE TRENDLINES GRP SP/ADR

OTC:TRNLY

TRNLY Rankings

TRNLY Stock Data

41.81M
431.41M
Asset Management
Financial Services
Link
United States of America
M P Misgav